196 related articles for article (PubMed ID: 22481632)
1. Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA).
Sesmilo G; Gaztambide S; Venegas E; Picó A; Del Pozo C; Blanco C; Torres E; Álvarez-Escolà C; Fajardo C; García R; Cámara R; Bernabeu I; Soto A; Villabona C; Serraclara A; Halperin I; Alcázar V; Palomera E; Webb SM;
Pituitary; 2013 Mar; 16(1):115-21. PubMed ID: 22481632
[TBL] [Abstract][Full Text] [Related]
2. [Epidemiology of acromegaly in Spain].
Sesmilo G
Endocrinol Nutr; 2013 Oct; 60(8):470-4. PubMed ID: 23246411
[TBL] [Abstract][Full Text] [Related]
3. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: MANAGEMENT OF ACROMEGALY PATIENTS: WHAT IS THE ROLE OF PRE-OPERATIVE MEDICAL THERAPY?
Fleseriu M; Hoffman AR; Katznelson L;
Endocr Pract; 2015 Jun; 21(6):668-73. PubMed ID: 26135961
[TBL] [Abstract][Full Text] [Related]
4. Medical treatment of acromegaly-experience from the Croatian acromegaly registry.
Solak M; Kraljević I; Popovac H; Šambula L; Polovina TŠ; Balaško A; Tomšić KZ; Dušek T; Novak A; Tripolski M; Kaštelan D
Endocrine; 2023 Sep; 81(3):555-561. PubMed ID: 37389718
[TBL] [Abstract][Full Text] [Related]
5. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
[TBL] [Abstract][Full Text] [Related]
6. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
Losa M; Garbin E; Pedone E; Mortini P
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).
Mestron A; Webb SM; Astorga R; Benito P; Catala M; Gaztambide S; Gomez JM; Halperin I; Lucas-Morante T; Moreno B; Obiols G; de Pablos P; Paramo C; Pico A; Torres E; Varela C; Vazquez JA; Zamora J; Albareda M; Gilabert M
Eur J Endocrinol; 2004 Oct; 151(4):439-46. PubMed ID: 15476442
[TBL] [Abstract][Full Text] [Related]
8. Management of acromegaly: is there a role for primary medical therapy?
Bush ZM; Vance ML
Rev Endocr Metab Disord; 2008 Mar; 9(1):83-94. PubMed ID: 18163213
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up results of multimodal treatment with initial surgical approach for acromegaly in a single center.
Van Rompaey K; Unuane D; Moens M; Duerinck J; Poppe K; Velkeniers B; D'Haens J
Acta Neurol Belg; 2013 Mar; 113(1):49-54. PubMed ID: 22975835
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Ciresi A; Radellini S; Guarnotta V; Giordano C
BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
[TBL] [Abstract][Full Text] [Related]
11. Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly.
van der Lely AJ; Kuhn E; Muhammad A; Coopmans EC; Neggers SJ; Chanson P
Eur J Endocrinol; 2020 Jun; 182(6):D17-D29. PubMed ID: 32234975
[TBL] [Abstract][Full Text] [Related]
12. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
[TBL] [Abstract][Full Text] [Related]
13. MANAGEMENT OF ENDOCRINE DISEASE: Individualised management of acromegaly.
Bollerslev J; Heck A; Olarescu NC
Eur J Endocrinol; 2019 Aug; 181(2):R57-R71. PubMed ID: 31100716
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
15. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
[TBL] [Abstract][Full Text] [Related]
16. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acromegaly.
Holdaway IM
Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805
[TBL] [Abstract][Full Text] [Related]
18. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
[TBL] [Abstract][Full Text] [Related]
19. The role of combination medical therapy in the treatment of acromegaly.
Lim DS; Fleseriu M
Pituitary; 2017 Feb; 20(1):136-148. PubMed ID: 27522663
[TBL] [Abstract][Full Text] [Related]
20. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
Wildemberg LE; da Silva Camacho AH; Miranda RL; Elias PCL; de Castro Musolino NR; Nazato D; Jallad R; Huayllas MKP; Mota JIS; Almeida T; Portes E; Ribeiro-Oliveira A; Vilar L; Boguszewski CL; Winter Tavares AB; Nunes-Nogueira VS; Mazzuco TL; Rech CGSL; Marques NV; Chimelli L; Czepielewski M; Bronstein MD; Abucham J; de Castro M; Kasuki L; Gadelha M
J Clin Endocrinol Metab; 2021 Jun; 106(7):2047-2056. PubMed ID: 33686418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
